Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05463848 | Surgical Pembro +/- Olaparib w TMZ for rGBM | active not recruiting | Phase 2 | 52 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT02223208 | Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13) | completed | Phase 1 / Phase 2 | 89 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02977780 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | recruiting | Phase 2 | 460 | David Reardon, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy | not yet recruiting | Phase 1 / Phase 2 | 10 | BreakBio CorpINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06319027 | Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial(GABLE) | recruiting | Phase 2 | 100 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05607407 | Methimazole in Patients With Progressive Glioblastoma | suspended | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow(GLADIATOR) | recruiting | Phase 2 | 60 | Tata Memorial CentreOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03409432 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | completed | Phase 2 | 26 | John ReneauOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07758062 | Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma(ELITE) | not yet recruiting | Phase 2 | 140 | Tianjin Medical University General HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04469075 | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07501559 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | recruiting | Phase 1 / Phase 2 | 40 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754734 | STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation | not yet recruiting | Phase 2 | 138 | Dongguan People's HospitalOTHER_GOV | 0 | Aug 10, 2026 | clinicaltrials |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma | not yet recruiting | Phase 1 / Phase 2 | 113 | Jubilant Therapeutics Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03862430 | A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM(RESTORE) | active not recruiting | Phase 2 | 87 | NuvOx LLCINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07003542 | A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas | recruiting | Phase 2 | 48 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05708352 | A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | recruiting | Phase 2 | 170 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03643549 | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)(BORTEM-17) | recruiting | Phase 1 / Phase 2 | 63 | Haukeland University HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03868943 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma(JAZZ) | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | active not recruiting | Phase 2 / Phase 3 | 447 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06069726 | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial(MOAB) | recruiting | Phase 2 | 80 | Duke UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | recruiting | Phase 1 / Phase 2 | 55 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma(GBM AGILE) | recruiting | Phase 2 / Phase 3 | 2,250 | Global Coalition for Adaptive ResearchOTHER | 6 | Jul 30, 2026 | clinicaltrials |
| NCT05781321 | Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | active not recruiting | Phase 2 | 170 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06991101 | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 190 | Baptist Health South FloridaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07735819 | Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma | not yet recruiting | Phase 2 | 61 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03180502 | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma | active not recruiting | Phase 2 | 120 | NRG OncologyOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT01339052 | Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma | completed | Phase 2 | 65 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07717580 | Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)(BV-LISA-CTCL) | not yet recruiting | Phase 2 | 46 | Peking University First HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05879250 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 39 | Northwestern UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06672575 | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06177964 | Lerapolturev (PVSRIPO) in GBM | recruiting | Phase 2 | 92 | Darell BignerOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715097 | Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07225621 | Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 103 | Alpheus Medical, Inc.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01352520 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | active not recruiting | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03541902 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03581292 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 5 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04623931 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03919071 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | active not recruiting | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT04485949 | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | active not recruiting | Phase 2 | 99 | ImvaxINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | active not recruiting | Phase 2 | 34 | ImmunityBio, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06805305 | DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | recruiting | Phase 2 | 180 | Diakonos Oncology CorporationINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02177578 | Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 29, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials